Trial Profile
Comparison of the efficacy of gefitinib in patients with non-small cell lung cancer according to the type of epidermal growth factor receptor mutation.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Nov 2015
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 28 Nov 2015 New trial record